Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals

Abstract Introduction This analysis evaluated the cost-effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) from the perspective of Australian state hospital payers. Methods A cost–utility analysis consisting of a decision tree and Markov cohort designed to calculate the differ...

Full description

Saved in:
Bibliographic Details
Main Authors: Ian R. Woodcock, Didu S. Kariyawasam, Maina P. Kava, Eppie M. Yiu, Damian Clark, Jane Adams, Matthias Bischof, Adrian Peacock, Colman Taylor, Nicholas J. C. Smith
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Neurology and Therapy
Subjects:
Cost-utility analysis
Newborn screening
Nusinersen
Onasemnogene abeparvovec
Spinal muscular atrophy
Online Access:https://doi.org/10.1007/s40120-025-00744-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-025-00744-8

Similar Items